Amantadine in pediatric patients with traumatic brain injury - A retrospective, case-controlled study

被引:31
作者
Green, LB [1 ]
Hornyak, JE [1 ]
Hurvitz, EA [1 ]
机构
[1] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48103 USA
关键词
rehabilitation; traumatic brain injury; amantadine; pediatric;
D O I
10.1097/01.PHM.0000143400.15346.C8
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Objective: To determine if amantadine use in pediatric patients with traumatic brain injury is well tolerated and to attempt to assess its effectiveness. Design: This was a retrospective, case-controlled study. Results: Of the 54 patients, aged 3-18 yrs, who were administered amantadine, five (9%) had side effects that might have been related to the drug. These included hallucinations, delusions, increased aggression, and nausea/vomiting. The side effects were reversed when the medication was stopped or the dosage decreased. Patients in the amantadine group had a greater increase in Ranchos Los Amigos level during their admission than those in the control group (median, 3 vs. 2; P < 0.01). This difference may be, at least in part, explained by the fact that the amantadine group started at a lower Ranchos Los Amigos level (median, 3 vs. 4; P < 0.01). There were subjective improvements noted in 29 of the 46 patients (63%) in the amantadine group whose full charts were available for review. Conclusion: Amantadine is a well tolerated medication when it is used in pediatric patients with traumatic brain injury. Subjective improvements were noted in the majority of the patients administered amantadine, and the amantadine group showed a greater improvement in Ranchos Los Amigos level during admission, suggesting that it may be effective.
引用
收藏
页码:893 / 897
页数:5
相关论文
共 23 条
[1]  
ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64
[2]   CLINICAL PHARMACOKINETICS OF AMANTADINE HYDROCHLORIDE [J].
AOKI, FY ;
SITAR, DS .
CLINICAL PHARMACOKINETICS, 1988, 14 (01) :35-51
[3]   REGIONAL DISTRIBUTION OF MONO-AMINES IN THE CEREBRAL-CORTEX AND SUB-CORTICAL STRUCTURES OF THE RHESUS-MONKEY - CONCENTRATIONS AND INVIVO SYNTHESIS RATES [J].
BROWN, RM ;
CRANE, AM ;
GOLDMAN, PS .
BRAIN RESEARCH, 1979, 168 (01) :133-150
[4]  
CHANDLER M, 1988, BRAIN INJURY, V4, P309
[5]   AMANTADINE TREATMENT OF A PATIENT WITH ANOXIC BRAIN INJURY [J].
EDBY, K ;
LARSSON, J ;
EEK, M ;
VONWENDT, L ;
OSTERGARD, B .
CHILDS NERVOUS SYSTEM, 1995, 11 (10) :607-609
[6]   PHARMACOLOGICAL CHANGES IN DOPAMINERGIC SYSTEMS INDUCED BY LONG-TERM ADMINISTRATION OF AMANTADINE [J].
GIANUTSOS, G ;
CHUTE, S ;
DUNN, JP .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 110 (03) :357-361
[7]   AMANTADINE - A NEW CLINICAL PROFILE FOR TRAUMATIC BRAIN INJURY [J].
GUALTIERI, T ;
CHANDLER, M ;
COONS, TB ;
BROWN, LT .
CLINICAL NEUROPHARMACOLOGY, 1989, 12 (04) :258-270
[8]  
HERRMANN EC, 1960, P SOC EXP BIOL MED, V103, P625, DOI 10.3181/00379727-103-25617
[9]   Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation [J].
Karli, DC ;
Burke, DT ;
Kim, HJ ;
Calvanio, R ;
Fitzpatrick, M ;
Temple, D ;
MacNeil, M ;
Pesez, K ;
Lepak, P .
BRAIN INJURY, 1999, 13 (01) :63-68
[10]  
KRACH LE, 1999, PEDIAT REHABILITATIO, P245